659 related articles for article (PubMed ID: 29923081)
1. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
4. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
6. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
8. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
9. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
10. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
Memon H; Patel BM
Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
[TBL] [Abstract][Full Text] [Related]
12. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
13. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
15. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
17. Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA; Reader J; Roque DM
Curr Treat Options Oncol; 2018 Nov; 19(12):74. PubMed ID: 30430276
[TBL] [Abstract][Full Text] [Related]
18. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
20. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]